Trial · NCT02487979
Adverse events41
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 41
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Mucositis oral | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Nausea | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Pain | General disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Infections and infestations - Other, specify | Infections and infestations | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Lymphocyte count decreased | Investigations | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Neutrophil count decreased | Investigations | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Hypokalemia | Metabolism and nutrition disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Somnolence | Nervous system disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Treatment (Glembatumumab Vedotin) | 2 | 22 | 2 |
| other | Hypertension | Vascular disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| serious | Anemia | Blood and lymphatic system disorders | Treatment (Glembatumumab Vedotin) | 2 | 22 | 2 |
| serious | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| serious | Abdominal pain | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| serious | Constipation | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| serious | Mucositis oral | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| serious | Nausea | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
| serious | Vomiting | Gastrointestinal disorders | Treatment (Glembatumumab Vedotin) | 1 | 22 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02487979/events